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Background: Our aim was to compare the 12-month incidence and clearance of oral high-risk HPV infection between
HIV-infected men who have sex with men (MSM) and HIV-negative MSM.
Methods: MSM aged 18 years or older were recruited in Amsterdam, the Netherlands. Questionnaire data and oral-rinse
and gargle samples were collected at baseline, and after 6 and 12 months. HPV DNA was genotyped using the
SPF10-PCR & DEIA-LiPA25 system (version 1). Determinants of oral HPV incidence and clearance were explored
using Cox and logistic regression analyses respectively.
Results: 433 HIV-negative and 290 HIV-infected MSM were included in these analyses. The median follow-up time
per participant was 12 months (range 3–15). During follow-up, 114 incident oral high-risk HPV infections were observed.
The incidence rate of HPV-16 was 3.5/1000 person-months (PM) in HIV-infected and 0.9/1000 PM in HIV-negative
MSM (IRR 4.1; 95% CI 1.3-13.2). The incidence rates of other high-risk HPV types ranged between 1.3-3.5/1000 PM
in HIV-infected and 0.0-1.1/1000 PM in HIV-negative MSM. In multivariable analyses, HIV infection (adjusted hazard
ratio [aHR] 3.8; 95% CI 2.3-6.2) and a higher number of recent oral sex partners (aHR 2.4 for ≥8 partners compared
to ≤2; 95% CI 1.4-4.2) were associated with HPV incidence. Of the 111 baseline oral high-risk infections, 59 (53.2%)
were cleared. In multivariable analyses, only a higher number of recent oral sex partners was associated with HPV
clearance (adjusted odds ratio 3.4 for ≥8 compared to ≤2 partners; 95% CI 1.3-9.0).
Conclusions: The incidence rate of oral high-risk HPV infection was higher in HIV-infected MSM and in those with
a higher number of recent oral sex partners. Just over half of the oral high-risk HPV infections at baseline were cleared
after 12 months, with a higher likelihood of clearance among MSM reporting higher numbers of recent oral sex
partners, but no difference by HIV status.
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Human Papillomavirus (HPV), in particular oral infection
with high-risk HPV type 16, has recently been recognized
as a main etiologic agent for a subset of head and neck
cancers [1]. Although the prevalence of oral high-risk
HPV infection is relatively low among the general popula-
tion, with estimates around 3.5% [2], a much higher preva-
lence of up to 25% has been reported among HIV-infected
men who have sex with men (MSM) [3,4].
The natural history of oral HPV infection is not yet well
understood. Previous studies suggest that the incidence
rate of oral HPV infection is lower than that of anal and
genital HPV infections [5-7], whereas the clearance rate
seems similar or higher compared to genital and anal
HPV infection [5,6,8]. Oral sex is thought to be the most
important risk factor of prevalent oral HPV infection, but
also male gender, increasing age, a higher number of
recent or lifetime partners, current smoking and HIV-
infection have often been associated with oral HPV infec-
tion [3,4,9,10]. Factors that have been associated with
incident and persistent infections differ across studies.
Recent data suggest that older age and current smoking
could be stronger risk factors for oral HPV persistence
than the acquisition [5,8].
Data reported on the incidence and clearance rates of
oral high-risk HPV among (HIV-infected) MSM are scarce,
especially those describing the effect of HIV-infection
[7,11,12]. As HIV-infected MSM are at increased risk of
HPV infection and HPV-related head and neck cancer
[13,14], our aim was to compare the 12-month incidence
and clearance of oral high-risk HPV infection between
HIV-infected and HIV-negative MSM participating in the
HIV & HPV in MSM (H2M) cohort in Amsterdam, the
Netherlands. In addition, we aimed to assess determinants
for oral high-risk HPV incidence and clearance.
In an earlier paper regarding the H2M cohort, we re-
ported 6-month incidence and clearance data of oral HPV
infections [15], but we were not able to estimate incidence
rates because of limited follow-up time. In the current
report covering a longer follow-up period with three
measurements per participant, we were able to estimate
incidence rates of individual high-risk HPV types, and
to assess the effect of HIV infection on time to infection.
We also studied clearance using a more rigorous defin-
ition (requiring two negative sample results after a positive




The Medical Ethics Committee of the Academic Medical
Center (AMC) Amsterdam approved this study, and all
participants provided written informed consent prior to
participation.Study participants and sample collection
The H2M study design and sample collection methods have
been described previously [4,15]. In brief, HIV-negative and
HIV-infected MSM aged 18 years or older were recruited
for a prospective cohort study in 2010–2011 in Amsterdam.
Data were collected at baseline, and after 6 and 12 months
follow-up. At each visit, participants provided oral samples
by rinsing and gargling for 30 seconds using 10–15 ml
Scope mouthwash (Procter & Gamble, Toronto, Ontario),
and completed detailed risk-factor questionnaires. HIV-
related data at baseline were obtained from the Dutch HIV
Monitoring Foundation’s national HIV patient database.
HPV DNA genotyping and classification
Processing of the oral samples and HPV DNA genotyping
methods have been described before [4]. DNA extraction
was performed using the MagNA Pure LC Total Nucleic
Acid Isolation Kit (Roche, Mannheim, Germany), and
subsequently HPV DNA amplification was performed
using the highly sensitive SPF10-PCR DEIA/LiPA25 system
(version 1) [16]. LiPA25 allows simultaneous identification
of 25 specific mucosal HPV genotypes, of which the fol-
lowing were classified as high-risk types: 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, and 59 [1].
Statistical analyses
Since participants could have been infected with or be
at risk for more than one high-risk HPV type, the main
outcomes of interest were time to incidence of oral type-
specific high-risk HPV infections, and clearance of type-
specific HPV infections. An incident HPV infection was
defined as a type-specific positive test result at 6 or
12 months follow-up in a participant who was free of
that specific HPV type at baseline. For incidence analyses,
we assumed that a new infection occurred at the midpoint
between the date of the first detection and the date of the
prior negative test result. Incidence rate ratios (IRR) were
calculated using Poisson regression. Kaplan-Meier curves
were constructed to explore the cumulative probability
of type-specific HPV incidence; log-rank tests were used
to compare HIV-infected and HIV-negative MSM. We
assessed the independent effect of HIV infection on
time to incident oral high-risk HPV infection using the
Wei-Lin-Weissfeld method, which is basically a Cox model
stratified by HPV type, to account for multiple HPV infec-
tions per person, while adjusting for within-subject cor-
relations [17]. We also explored determinants associated
with incident oral high-risk HPV infection stratified by
HIV-status using the Wei-Lin-Weissfeld method. Multi-
variable analyses could not be performed for HIV-negative
MSM due to low numbers of incident infections.
Among participants who tested positive at baseline,
type-specific clearance of oral high-risk HPV infections
was explored. Clearance was defined as a participant
van Aar et al. BMC Infectious Diseases  (2014) 14:668 Page 3 of 8testing negative at two consecutive visits after a preva-
lent infection at baseline. Persistence was defined as a
participant testing positive at two consecutive visits
after a prevalent infection at baseline. Participants with
a missing visit were excluded from these analyses. To
assess the independent effect of HIV infection on clearance,
logistic regression analyses were performed, with general-
ized estimating equations (GEEs) to account for multiple
HPV infections per person, assuming an exchangeable cor-
relation structure [9]. Because of low numbers of oral HPV
infections at baseline, determinants associated with clear-
ance could not be examined stratified by HIV status.
For both incidence and clearance analyses, variables that
were biologically plausible as well as known determinants
from the literature were included a priori in the multivari-
able models. P-values were considered statistically signifi-
cant at P < 0.05. All analyses were performed using Stata
(version 13.0; Stata Corp, College Station, Texas, USA).
Results
Study participants
Of the 795 participants that were enrolled in the H2M
study (previously described [18]), 723 were included in the
current analyses. Participants for whom data collection
was incomplete (i.e., no HPV test results and/or no ques-
tionnaire data, n = 72) were excluded. The 72 excluded
participants were younger than the 723 included partic-
ipants (rank-sum P = 0.046), but comparable with re-
spect to HIV status. At baseline, the median age was 38
(IQR 34–42) years among 433 HIV-negative MSM and
47 (IQR 40–53) years among 290 HIV-infected MSM
(P < 0.001). HIV-infected MSM generally showed higher
sexual risk behavior, e.g., the median number of lifetime
male sex partners was 300 (IQR 100–1000) for HIV-
infected MSM versus 100 (IQR 50–400) for HIV-
negative MSM (P < 0.001). The median follow-up time
was 370 days for HIV-negative MSM (IQR 356–384)
and 350 days for HIV-infected MSM (IQR 314–373; P <
0.001). Among HIV-infected MSM, the median CD4+ cell
count was 530 cells/mm3 (IQR 410–694), the median
nadir CD4+ cell count was 220 cells/mm3 (IQR 170–320),
and 79% (192/243) had an undetectable HIV viral load at
baseline.
Oral high-risk HPV incidence
In total, 114 incident oral high-risk HPV infections were
detected. For each HPV type, the incidence rate was higher
in HIV-infected than in HIV-negative MSM (Table 1). For
HPV-16, the incidence rate was 3.5/1000 person months
(PM) in HIV-infected MSM versus 0.9/1000 PM in HIV-
negative MSM, with an IRR of 4.1 (95% confidence
interval (CI) 1.3-13.2). The incidence rate of HPV-18
was 2.8/1000 PM and 0.4/1000 PM in HIV-infected and
HIV-negative MSM respectively (IRR 6.6; 95% CI 1.4-30.8). The 12-month cumulative incidence of HPV-16 was
4.0% in HIV-infected MSM and 1.0% in HIV-negative
MSM; for HPV-18 this was 3.0% in HIV-infected MSM
and 0.5% in HIV-negative MSM (Figure 1).
In multivariable analyses, incident oral high-risk HPV
infection was significantly associated with HIV infection
(adjusted hazard ratio (aHR) 3.8, 95% CI 2.3-6.2) and with
a higher number of recent oral sex partners among MSM
overall (aHR 2.4; 95% CI 1.4-4.2 for ≥8 compared to ≤2
partners). Among HIV-infected MSM only, a higher num-
ber of recent oral sex partners and both recent tobacco
smoking and cannabis use were associated with incident
oral high-risk HPV infection in multivariable analyses
(Table 2). Oral-anal contact in the previous six months
was significantly associated with incident oral high-risk
HPV infection in univariable analysis, but was not associ-
ated in multivariable analyses. We did not find an asso-
ciation of incident oral high-risk HPV infection with age
nor with nadir CD4+ cell count (Table 2).
Oral high-risk HPV clearance
At baseline, 111 oral high-risk HPV infections were ob-
served, of which 59 (53.2%) were cleared, 25 (22.5%) per-
sisted, and 27 (24.3%) showed other patterns (Table 3).
After 12 months, 38.5% (n = 5/13) and 55.6% (n = 5/9) of
the oral HPV-16 infections were cleared in HIV-infected
MSM and HIV-negative MSM respectively.
HIV status was borderline significantly associated with
clearance of HPV infection in univariable analysis, but
was not associated in multivariable analyses (aOR 0.5;
95% CI 0.2-1.3; Table 4). In multivariable analyses, a higher
number of recent oral sex partners was significantly and
positively associated with clearance of high-risk HPV
infection (adjusted odds ratio (aOR) 3.4; 95% CI 1.3-9.0
for ≥8 compared to ≤2 partners). Neither age nor tobacco
smoking were associated with oral high-risk HPV clear-
ance in uni- and multivariable analyses.
Discussion
In our cohort of HIV-negative and HIV-infected MSM, we
found that HIV infection was an independent determinant
for oral high-risk HPV incidence, and that around half of
the oral HPV infections were cleared within 12 months.
The type-specific incidence rates among HIV-negative
MSM (e.g. HPV-16: 0.9/1000 PM) were generally compar-
able to or somewhat higher than incidence rates reported
in a large multinational study among HIV-negative, mainly
heterosexual men (HPV-16: 0.8/1000 PM) [5], but the in-
cidence rates among HIV-infected MSM in our study were
substantially higher (HPV-16: 3.5/1000 PM). This indi-
cates that HIV infection may be an important determinant
for oral HPV incidence. This was even the case after ad-
justment for age, smoking, oral-anal contact and the num-
ber of recent oral sex partners. A higher number of recent
Table 1 The number of incident infectionsa, the incidence rate, and incidence rate ratios of individual oral high-risk
HPV types in HIV-negative and HIV-infected MSM (H2M study, Amsterdam 2010-2012)
HIV-negative MSM HIV-infected MSM HIV-infected versus HIV-negative MSM
No. PM Incidence rate per 1000 PM
(95% CI)
No. PM Incidence rate per 1000 PM
(95% CI)
IRR (95% CI) P-valueb
HPV-16 4 4675 0.9 (0.3 - 2.3) 10 2833 3.5 (1.9 - 6.6) 4.1 (1.3 - 13.2) 0.011
HPV-18 2 4750 0.4 (0.1 - 1.7) 8 2901 2.8 (1.4 - 5.5) 6.6 (1.4 - 30.8) 0.007
HPV-31 1 4782 0.2 (0.03 - 1.5) 7 2918 2.4 (1.1 - 5.0) 11.5 (1.4 - 93.2) 0.004
HPV-33 4 4732 0.8 (0.3 - 2.3) 10 2832 3.5 (1.9 - 6.6) 4.2 (1.3 - 13.3) 0.010
HPV-35 1 4727 0.2 (0.03 - 1.5) 4 2973 1.3 (0.5 - 3.6) 6.4 (0.7 - 56.9) 0.058
HPV-39 5 4701 1.1 (0.4 - 2.6) 4 2934 1.4 (0.5 - 3.6) 1.3 (0.3 - 4.8) 0.713
HPV-45 2 4775 0.4 (0.1 - 1.7) 4 2973 1.3 (0.5 - 3.6) 3.2 (0.6 - 17.5) 0.161
HPV-51 3 4693 0.6 (0.2 - 2.0) 10 2908 3.4 (1.9 - 6.4) 5.4 (1.5 - 19.5) 0.005
HPV-52 3 4743 0.6 (0.2 - 2.0) 8 2938 2.7 (1.4 - 5.4) 4.3 (1.1 - 16.2) 0.020
HPV-56 3 4750 0.6 (0.2 - 2.0) 9 2897 3.1 (1.6 - 6.0) 4.9 (1.3 - 18.2) 0.009
HPV-58 0 4798 − 7 2972 2.4 (1.1 - 4.9) −
HPV-59 1 4770 0.2 (0.03 - 1.5) 4 3001 1.3 (0.5 - 3.6) 6.4 (0.7 - 56.9) 0.058
Abbreviations: MSM men who have sex with men, No. number, PM person months, CI confidence interval, IRR incidence rate ratio.
aAn incident infection was defined as a positive test result at 6 or 12 months follow-up in a participant who was free of that specific HPV type at baseline.
bSignificant P values are in bold.
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HPV incidence, which is in line with previous reports sug-
gesting that oral sexual behavior may be a risk factor for
both oral HPV prevalence [3,9] and HPV-related head and
neck cancer [19].
Although oral high-risk HPV clearance was generally
lower among HIV-infected MSM, HIV infection was not
a significant determinant for clearance in multivariable
analyses. Strikingly, a higher number of recent oral sex
partners was significantly associated with increased oral
HPV clearance. We hypothesize that newly acquired
HPV infections (which may be more common amongFigure 1 Cumulative probability of oral HPV-16 and HPV-18 infection
HIV-infected MSM (red lines) and HIV-negative MSM (blue lines) (H2M stud
with men; H2M = HIV & HPV in MSM.participants with more recent oral sex partners) are more
likely to clear within one year, as compared to long-standing
persistent infections [6]. This finding could also be explained
by the fact that our method of HPV detection was
based on the detection of HPV DNA which is not ne-
cessarily indicative of an active infection. Therefore, the
higher clearance rate in those with a higher number of re-
cent oral sex partners might be because part of the oral
HPV in this group could be detections rather than actual
active infections.
The current study builds on data previously published,
in which the 6-month oral high-risk HPV incidence and. The cumulative probability of oral HPV-16 and HPV-18 infection in
y, Amsterdam 2010–2012). Abbreviations: MSM =men who have sex
Table 2 Univariable and multivariable analyses of determinants of incident oral high-risk HPV infectiona in HIV-negative MSM and HIV-infected MSM using the
Wei-Lin-Weissfeld method (H2M study, Amsterdam 2010–2012)
HIV-infected MSM and HIV-negative MSM HIV-infected MSM HIV-negative MSM
Univariable Multivariable Univariable Multivariable Univariable
HR (95% CI) P-valueb aHR (95% CI) P-valueb HR (95% CI) P-valueb aHR (95% CI) P-valueb HR (95% CI) P-valueb
HIV infection <0.001 <0.001 n.a. n.a.
No 1.0 1.0
Yes 4.7 (3.0 - 7.5) 3.8 (2.3 - 6.2)
Age (years) by categoryc <0.001 0.215 0.715 0.356 0.524
≤ 34 1.0 1.0 1.0 1.0 1.0
35 - 44 1.4 (0.7 - 2.5) 1.0 (0.6 - 1.8) 0.9 (0.4 - 1.9) 0.7 (0.3 - 1.5) 1.6 (0.7 - 4.0)
≥ 45 2.7 (1.5 - 4.8) 1.5 (0.8 - 2.6) 1.1 (0.5 - 2.2) 1.1 (0.6 - 2.3) 1.7 (0.6 - 5.1)
Tobacco smoking and/or cannabis
use in previous 6 monthsd
0.002 0.051 0.010 0.017 0.650
No 1.0 1.0 1.0 1.0 1.0
Cannabis use only 2.6 (1.4 - 4.9) 1.5 (0.8 - 2.7) 2.5 (1.3 - 5.1) 1.9 (1.0 - 3.6) 0.9 (0.1 - 6.5)
Tobacco smoking only 1.9 (1.1 - 3.4) 2.0 (1.2 - 3.4) 2.8 (1.4 - 5.4) 2.7 (1.4 - 5.2) 0.9 (0.3 - 2.8)
Both cannabis use and tobacco smoking 2.4 (1.4 - 4.1) 1.8 (1.0 - 3.0) 2.1 (1.1 - 4.1) 2.0 (1.0 - 3.8) 1.7 (0.7 - 4.1)
Oral-anal contact in previous
6 months (rimming)
0.110 0.530 0.036 0.392 0.615
No 1.0 1.0 1.0 1.0 1.0
Yes 1.4 (0.9 - 2.2) 1.2 (0.7 - 1.9) 1.7 (1.0 - 2.8) 1.3 (0.7 - 2.5) 1.2 (0.5 - 2.8)
Number of oral sex partners in
previous 6 months by category
<0.001 <0.001 0.004 0.004 0.024
≤ 2 1.0 1.0 1.0 1.0 1.0
3 - 7 0.9 (0.5 - 1.7) 1.0 (0.5 - 1.9) 0.8 (0.4 - 1.7) 0.8 (0.4 - 1.7) 2.0 (0.6 - 6.9)
≥ 8 2.4 (1.4 - 4.0) 2.4 (1.4 - 4.2) 2.1 (1.2 - 3.7) 2.2 (1.1 - 4.4) 4.3 (1.4 - 13.5)
Nadir CD4 cell count (cells/mm3)
by categoryc
n.a. 0.108 0.115 n.a.
≤ 199 1.0 1.0
200 - 350 0.6 (0.3 - 1.1) 0.6 (0.3 - 1.0)
≥ 350 1.2 (0.6 - 2.3) 0.9 (0.4 - 1.9)
Abbreviations: MSM men who have sex with men, HR hazard ratio, CI confidence interval, aHR adjusted hazard ratio, n.a. not applicable.
aAn incident infection was defined as a positive test result at 6 or 12 months follow-up in a participant who was free of that specific HPV type at baseline.
bBased on Wald test. Significant P values are in bold.
cAs collected at baseline. All behavioral variables were based on questions asked during the follow-up visits; HIV infection status was time-updated.
dAs there was interaction between tobacco smoking and cannabis use, we created a combined variable. In case of missing values for tobacco smoking, baseline smoking status was carried forward. The route of















Table 3 Numbers and percentages (with 95% CI) of cleared oral high-risk HPV infections in HIV-negative and
HIV-infected MSMa (H2M study, Amsterdam 2010–2012)
12-month clearance of oral high-risk HPV infections
HIV-negative MSM HIV-infected MSM
No. % 95% CI No. % 95% CI P-valueb
HPV-16 5/9 55.6 (21.2 - 86.3) 5/13 38.5 (13.9 - 68.4) 0.666
HPV-18 2/3 66.7 (9.4 - 99.2) 3/6 50.0 (11.8 - 88.2) 1.000
HPV-31 1/1 100.0 (2.5 - 100.0)c 5/7 71.4 (29.0 - 96.3) 1.000
HPV-33 1/3 33.3 (0.8 - 90.6) 1/12 8.3 (0.2 - 38.5) 0.371
HPV-35 1/5 20.0 (0.5 - 71.6) 1/3 33.3 (0.8 - 90.6) 1.000
HPV-39 4/4 100.0 (39.8 - 100.0)c 2/6 33.3 (4.3 - 77.7) 0.076
HPV-45 0/0 - - 5/5 100.0 (47.8 -100.0)c -
HPV-51 5/6 83.3 (35.9 - 99.6) 3/5 60.0 (14.7 - 94.7) 0.545
HPV-52 3/3 100.0 (29.2 - 100.0)c 3/4 75.0 (19.4 - 99.4) 1.000
HPV-56 1/2 50.0 (1.3 - 98.7) 5/9 55.6 (21.2 - 86.3) 1.000
HPV-58 0/0 - - 1/2 50.0 (1.3 - 98.7) -
HPV-59 2/2 100.0 (15.8 - 100.0)c 0/1 0.0 (0.0 -97.5)c 0.333
Abbreviations: MSM men who have sex with men, No. number, CI confidence interval.
aClearance was defined as two consecutive negative results after a positive test result at baseline (1-0-0), persistence was defined as two consecutive positive
results after a positive test result at baseline (1-1-1), other infection patterns (1-0-1 or 1-1-0) did not meet criteria for either clearance or persistence.
bBased on Fisher’s exact test.
cOne-sided: 97.5% CI.
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Most determinants identified in this report were compar-
able to those in our earlier report, notably the association
between HIV infection and oral HPV incidence. However,
in the earlier report an increasing number of recent oralTable 4 Univariable and multivariable analyses of determinan






Age (years) by categoryc
≤ 34 1.0





Number of oral sex partners last 6 months by category
≤ 2 1.0
3 - 7 1.4
≥ 8 3.6
Abbreviations: MSM men who have sex with men, OR odds ratio, aOR adjusted odds
aClearance was defined as two consecutive negative results after a positive test res
bBased on Wald test. Significant P values are in bold.
cAs collected at baseline. All other variables were based on data collected at the 6-
dIn case of missing values at the 6-month follow-up visit, baseline smoking status wsex partners was borderline significantly associated with
oral high-risk HPV incidence in multivariable analyses,
while in this report it was a strong and independent deter-
minant. Moreover, while in our previous report no deter-
minants for clearance were identified, we now observedts of clearancea of 111 oral high-risk HPV infections in
ating equations (H2M study, Amsterdam 2010–2012)
le Multivariable
(95% CI) P-valueb aOR (95% CI) P-valueb
0.049 0.167
1.0
(0.2 - 1.0) 0.5 (0.2 - 1.3)
0.233 0.494
1.0
(0.1 - 2.6) 0.3 (0.1 - 2.0)
(0.1 - 1.6) 0.4 (0.1 - 2.3)
0.696 0.910
1.0
(0.4 - 1.9) 1.1 (0.4 - 2.6)
0.018 0.030
1.0
(0.5 - 3.9) 1.2 (0.4 - 3.6)
(1.4 - 9.0) 3.4 (1.3 - 9.0)
ratio, CI confidence interval.
ult at baseline (1-0-0).
month follow-up visit.
as used.
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sex partners. Although the study population, sampling and
laboratory methods, and research questions were largely
the same, the current study adds important information: 1)
the follow-up time was doubled, which increased the
power of the study and enabled us to assess incidence
rates, which facilitates comparisons across studies, and 2)
we used a stricter definition of clearance (requiring two
negative samples after a positive sample).
This study has some limitations. First, despite the in-
creased follow-up time, the current study still had limited
power, especially in the analyses of HPV clearance in HIV-
negative MSM. Second, it has been reported that oral HPV
genotypes might be missed with a single oral rinse sample
and, that this sampling technique could be improved by
prior epithelial abrasion or by using multiple sampling
methods [20,21]. Although this potential error could have
impact on the accuracy of the incidence and clearance
rates, it would not have affected the difference in the inci-
dence or clearance rates between risk groups because the
error would be similar for each group. Finally, our analysis
of clearance was based on prevalent oral infections: the
duration of the infection before enrollment was unknown.
Long-term follow-up studies are needed to further assess
the natural history or oral HPV infection. Future research
could also investigate the role of oral health in acquisition
and persistence of oral high-risk HPV infections as recent
studies indicated that poor oral health is an independent
risk factor for oral HPV infection [22,23].
Conclusions
In conclusion, oral high-risk HPV incidence was independ-
ently associated with HIV infection and a higher number
of recent oral sex partners, while just over half of the
prevalent infections were cleared within 12 months. As
the incidence of HPV-related head and neck cancer is in-
creasing in many parts of the world [24-26], better under-
standing of the natural history of oral HPV infection is
essential for prevention of these HPV-related cancers,
especially among high-risk groups such as HIV-infected
MSM.
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